Holen Sie sich die Stockscreener-App
18.35
3.37%
-0.64
Schlusskurs vom Vortag:
$18.99
Offen:
$18.86
24-Stunden-Volumen:
224.44K
Relative Volume:
0.94
Marktkapitalisierung:
$578.49M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-29.59M
KGV:
-14.39
EPS:
-1.275
Netto-Cashflow:
$-18.35M
1W Leistung:
-6.23%
1M Leistung:
+77.98%
6M Leistung:
+116.90%
1J Leistung:
+124.05%
1-Tages-Spanne:
$18.02
$19.01
1-Wochen-Bereich:
$18.02
$20.74
52-Wochen-Spanne:
$5.55
$29.27
Nuvectis Pharma Inc Stock (NVCT) Company Profile
Firmenname
Nuvectis Pharma Inc
Sektor
Branche
Telefon
360-837-7232
Adresse
1 BRIDGE PLAZA, SUITE 275, FORT LEE
Compare NVCT vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NVCT
Nuvectis Pharma Inc
|
18.35 | 578.49M | 0 | -29.59M | -18.35M | -1.275 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Nuvectis Pharma Inc Stock (NVCT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-02 | Eingeleitet | Maxim Group | Buy |
| 2025-03-17 | Eingeleitet | Laidlaw | Buy |
| 2022-07-13 | Eingeleitet | Ladenburg Thalmann | Buy |
Nuvectis Pharma Inc Aktie (NVCT) Neueste Nachrichten
Nuvectis Pharma’s NXP900 Combo Trial Adds Fresh Momentum to NVCT in EGFR Lung Cancer - TipRanks
The Billion-Dollar Pill: With NXP100, Nuvectis Pharma Just Staked Its Claim in the New Biotech Gold Rush - TipRanks
Wall Street analysts see a 61.46% upside in Nuvectis Pharma (NVCT): Can the stock really move this high? - MSN
Wall Street Analysts See a 61.46% Upside in Nuvectis Pharma (NVCT): Can the Stock Really Move This High? - Yahoo Finance
Roth MKM Maintains Nuvectis Pharma(NVCT.US) With Buy Rating, Maintains Target Price $33 - Moomoo
Nuvectis Pharma Price Target Raised to $33.00/Share From $20.00 by Roth Capital - Moomoo
Roth Capital raises Nuvectis target to $33 - scanx.trade
Roth MKM Maintains Nuvectis Pharma(NVCT.US) With Buy Rating, Raises Target Price to $33 - Moomoo
An Insider Of Nuvectis Pharma Picks Up 1.5% More Stock - 富途牛牛
Trading Systems Reacting to (NVCT) Volatility - Stock Traders Daily
What makes Nuvectis Pharma, Inc. (NVCT) a strong momentum stock: Buy now? - MSN
Nuvectis Pharma announces public share offering to support drug programs - MSN
Nuvectis Pharma Announces Major Public Equity Offering - The Globe and Mail
Insider Buying: Ron Bentsur Acquires Additional Shares of Nuvect - GuruFocus
Nuvectis Pharma CEO Ron Bentsur buys $250,000 in company stock By Investing.com - Investing.com Nigeria
Nuvectis Pharma CEO Ron Bentsur buys $250,000 in company stock - Investing.com
[Form 4] Nuvectis Pharma, Inc. Insider Trading Activity - Stock Titan
Form 4 Nuvectis Pharma Inc For: 1 July By Investing.com - Investing.com India
Nuvectis Pharma 10% owner Mosseri buys $916k in shares - Investing.com UK
Nuvectis Pharma 10% owner Mosseri buys $916k in shares By Investing.com - Investing.com Australia
Nuvectis Pharma (NVCT) CEO Ron Bentsur buys $250,000 in shares - Stock Titan
Nuvectis: 'Hold' On NXP800 Removal And Newly Licensed Candidates (NASDAQ:NVCT) - Seeking Alpha
What Makes Nuvectis Pharma, Inc. (NVCT) a Strong Momentum Stock: Buy Now? - Yahoo Finance
Nuvectis Raises $100M for Oncology Pivot - AllSci
Form 424B5 Nuvectis Pharma Inc For: 30 June - Investing.com UK
Form 424B5 Nuvectis Pharma Inc For: 30 June By Investing.com - Investing.com Nigeria
Nuvectis Pharma Sets 5M-Share, $20 Offering; ~$93M Net, Cantor Fitzgerald Underwriter - TradingView
Nuvectis Pharma (NASDAQ: NVCT) to raise $100M in stock sale - Stock Titan
Nuvectis Pharma (NVCT) files $100M offering; 5.0M shares at $20.00 - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
Nuvectis gains two experimental drugs in licensing deal with China's Haisco - MSN
Nuvectis shares continue to rally after $1.46B Haisco deal - BioWorld News
Nuvectis Pharma shares slide after pricing $100 million discounted stock offering (NVCT) - Yahoo Finance
Concentrix Reports Downbeat Q2 Earnings, Joins Nuvectis Pharma, Vishay Intertechnology And Other Big Stoc - Benzinga
Nuvectis Pharma stock tumbles 25% on discounted offering By Investing.com - Investing.com Canada
Nuvectis Pharma Prices $100 Million Secondary Stock Offering; Shares Down Pre-Bell - Moomoo
Nuvectis Pharma's $100 Million Offering: Dilution at a Discount Amidst Pipeline Hopes - Kavout | AI
Nuvectis locks in $100M from 5 million-share stock sale - Stock Titan
Nuvectis Pharma Intends to Use Net Proceeds From Offering to Advance Development Programs >NVCT - Moomoo
Concentrix Reports Downbeat Q2 Earnings, Joins Nuvectis Pharma, Vishay Intertechnology And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session - Sahm
Nuvectis Pharma prices $100 million public offering at $20/share By Investing.com - Investing.com Australia
Nuvectis Pharma prices $100 million public offering at $20/share - Investing.com
Nuvectis Pharma Prices $100 Million Underwritten Public Offering of Common Stock - Quiver Quantitative
Nuvectis Pharma Announces Pricing of $100 Million Public Offering of Common Stock - GlobeNewswire
Form 424B5 Nuvectis Pharma Inc For: 29 June By Investing.com - Investing.com India
Form 424B5 Nuvectis Pharma Inc For: 29 June - Investing.com UK
Finanzdaten der Nuvectis Pharma Inc-Aktie (NVCT)
Umsatz
Nettogewinn
Free Cashflow
ENV
Nuvectis Pharma Inc-Aktie (NVCT) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| BENTSUR RON | Chairman & CEO |
Jun 30 '26 |
Buy |
20.00 |
12,500 |
250,000 |
3,688,424 |
| BENTSUR RON | Chairman & CEO |
Nov 05 '25 |
Buy |
5.72 |
5,000 |
28,600 |
3,525,924 |
| Sanchez Juan | Director |
Nov 05 '25 |
Buy |
5.79 |
13,000 |
75,270 |
78,150 |
| Kaplan Matthew L. | Director |
Nov 05 '25 |
Buy |
5.84 |
11,000 |
64,240 |
124,760 |
| Mosseri Marlio Charles | 10% Owner |
Oct 27 '25 |
Buy |
6.28 |
72,836 |
457,410 |
3,136,576 |
| Mosseri Marlio Charles | 10% Owner |
Oct 23 '25 |
Buy |
6.06 |
46,900 |
284,214 |
3,028,706 |
| Mosseri Marlio Charles | 10% Owner |
Oct 24 '25 |
Buy |
6.15 |
35,034 |
215,459 |
3,063,740 |
2.64%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):